Validation of the rapid and simple LC-MS/MS method for the quantification of pregabalin in plasma of acutely poisoned patients

• Autorzy: Antunovic Marko , Dzudovic Jelena , Kilibarda Vesna , Vucinic Slavica , Djordjevic Snezana

Identyfikatory

DOI

10.1556/1326.2023.01104

• Języki publikacji: EN

Abstrakty

EN

Pregabalin is a gabapentinoid approved for the treatment of general anxiety disorder, neuropathic pain and as adjunctive therapy for focal seizures in patients with epilepsy. In addition, there are a number of conditions for which pregabalin is prescribed off-label. Along with the widespread use there are a significant number of reports describing the misuse of pregabalin over the last decade. Over time, it became clear that pregabalin should become part of routine testing in toxicology laboratories. The aim of this paper was to present validation of a LC-MS/MS method for the quantification of pregabalin in plasma of acutely poisoned patients. Simple sample preparation step and rapid chromatographic separation shortened the overall analysis time, which was the goal of method development. The presence of pregabalin was confirmed with three ion transitions, ensuring high selectivity of the validated method. The statistical data obtained showed good precision and accuracy over a wide concentration range. No endogenous or other interference was detected, and there was no matrix effect influence with this method. The LC-MS/MS method was applied to quantify pregabalin in plasma samples of patients admitted to the emergency department due to a possible acute pregabalin overdose. Different concentrations were found, and we report, to the best of our knowledge, the highest plasma concentration of pregabalin in the plasma of a patient with acute poisoning. In conclusion, we developed a fast and simple LC-MS/MS method for reliable determination of pregabalin and demonstrated the developed method was suitable for routine use in clinical toxicology setting.

Słowa kluczowe

EN

abuse; overdose; gabapentinoids; liquid chromatography; tandem mass spectrometry

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2024
• Tom: Vol. 36, no. 2
• Strony: 106--113
• Opis fizyczny: Bibliogr. 22 poz., rys., wykr.

Twórcy

autor

Antunovic Marko

• Medical Faculty Military Medical Academy, University of Defense, Belgrade, Serbia
• National Poison Control Center, Military Medical Academy, Belgrade, Serbia

• https://orcid.org/0000-0002-8458-1919

autor

Dzudovic Jelena

• National Poison Control Center, Military Medical Academy, Belgrade, Serbia

autor

Kilibarda Vesna

• Medical Faculty Military Medical Academy, University of Defense, Belgrade, Serbia
• National Poison Control Center, Military Medical Academy, Belgrade, Serbia

autor

Vucinic Slavica

• Medical Faculty Military Medical Academy, University of Defense, Belgrade, Serbia
• National Poison Control Center, Military Medical Academy, Belgrade, Serbia

autor

Djordjevic Snezana

• Medical Faculty Military Medical Academy, University of Defense, Belgrade, Serbia
• National Poison Control Center, Military Medical Academy, Belgrade, Serbia

Bibliografia

• 1. Chincholkar, M. Br. J. Pain 2020, 14(2), 104–14.
• 2. Evoy, K. E.; Peckham, A. M.; Covvey, J. R.; Tidgewell, K. J. J. Clin. Pharmacol. 2021, 61(Suppl. 2), S89–99.
• 3. Patsalos, P. N.; Spencer, E. P.; Berry, D. J. Ther. Drug Monit. 2018, 40(5), 526–48.
• 4. Slocum, G. W.; Schult, R. F.; Gorodetsky, R. M.; Wiegand, T. J.; Kamali, M.; Acquisto, N. M. Toxicol. Commun. 2018, 2(1), 19–20.
• 5. Braga, A. J.; Chidley, K. Anaesthesia 2007, 62(5), 524–7.
• 6. Elliott, S. P.; Burke, T.; Smith, C. J. Forensic Sci. 2017, 62(1), 169–73.
• 7. Wood, D. M.; Berry, D. J.; Glover, G.; Eastwood, J.; Dargan, I. P. J. Med. Toxicol. 2010, 6(4), 435–7.
• 8. Cairns, R.; Schaffer, A. L.; Ryan, N.; Pearson, P. A.; Buckley, N. A. Addiction 2019, 114(6), 1026–34.
• 9. Daly, C.; Griffin, E.; Ashcroft, D. M.; Webb, R. T.; Perry, I. J.; Arensman, E. Clin. Drug Investig. 2018, 38(4), 373–80.
• 10. Dufayet, L.; Care, W.; Deheul, S.; Laborde-Casterot, H.; Nisse, P.; Langrand, J.; Vodovar, D. Clin. Toxicol. 2021, 59(11), 1027–30.
• 11. Rietjens, S. J.; Sikma, M. A.; Hunault, C. C.; De Lange, D. W.; Hondenbrink, L. Br. J. Clin. Pharmacol. 2022 Mar, 88(3), 1288–97.
• 12. Isoardi, K. Z.; Polkinghorne, G.; Harris, K.; Isbister, G. K. Br. J. Clin. Pharmacol. 2020 Dec, 86(12), 2435–40.
• 13. Dwivedi, J.; Namdev, K. K.; Chilkoti, D. C.; Verma, S.; Sharma, S. Ther. Drug Monit. 2018, 40(5), 610–9.
• 14. Vaidya, V. V.; Yetal, S. M.; Roy, S. M. N.; Gomes, N. A.; Joshi, S. S. Chromatographia 2007, 66(11–12), 925–8.
• 15. Shah, G. R.; Ghosh, C.; Thaker, B. T. J. Adv. Pharm. Technol. Res. 2010 Jul, 1(3), 354–7.
• 16. Martinc, B.; Roškar, R.; Grabnar, I.; Vovk, T. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 2014, 962, 82–8.
• 17. De La Vega, H.; Fox, K.; Pardi, J.; Santiago-Tirado, W.; Cooper, G. J. Anal. Toxicol. 2019, 43(9), 696–702.
• 18. Nahar, L.; Smith, A.; Patel, R.; Andrews, R.; Paterson, S. J. Anal. Toxicol. 2017, 41(5), 441–50.
• 19. European Medicines Agency Guideline on bioanalytical method validation, 2011 Jul. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (accessed September, 2022).
• 20. Souverain, S.; Rudaz, S.; Veuthey, J. L. J. Pharm. Biomed. Anal. 2004, 35(4), 913–20.
• 21. Allen, K. R. Clin. Toxicol. (Phila). 2006, 44(2), 147–53.
• 22. Armbruster, D. A.; Pry, T. Clin. Biochem. Rev. 2008, (Suppl 1), S49–52.